Publications of Luis A. Pardo
All genres
Journal Article (94)
61.
Journal Article
5 (1), e8858 (2010)
Characterization of Eag1 channel lateral mobility in rat hippocampal cultures by single-particle-tracking with quantum dots. PLoS ONE 62.
Journal Article
9 (2), pp. 918 - 924 (2010)
EAG1, EAG2 and KCNN3 gene brain expression of isolated reared rats. Genes, Brain and Behavior 63.
Journal Article
2 (5), pp. 745 - 755 (2010)
K+ channels as therapeutic targets in oncology. Future Medicinal Chemistry 64.
Journal Article
8, pp. 982 - 1001 (2009)
Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery 65.
Journal Article
70 (2), pp. 286 - 293 (2009)
Concept of a selective tumour therapy and its evaluation by near-infrared fluorescence imaging and flat-panel volume computed tomography in mice. European Journal of Radiology 66.
Journal Article
38 (3), pp. 279 - 284 (2009)
The voltage dependence of hEag currents is not determined solely by membrane-spanning domains. European Biophysics Journal 67.
Journal Article
283 (52), pp. 36234 - 36240 (2008)
Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. Journal of Biological Chemistry 68.
Journal Article
68 (6), pp. 1611 - 1613 (2008)
Eag1: an emerging oncological target. Cancer Research 69.
Journal Article
9 (6), pp. 512 - 515 (2008)
Ion channels: functional expression and therapeutic potential in cancer. Colloquium on ion channels and cancer. EMBO Reports 70.
Journal Article
30, pp. 162 - 173 (2008)
Pattern of axonal injury in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Neurobiology of Disease 71.
Journal Article
155, pp. 833 - 844 (2008)
Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neuroscience 72.
Journal Article
12 (7), pp. 837 - 843 (2008)
Eag1 as a cancer target. Expert Opinion on Therapeutic Targets 73.
Journal Article
67 (15), pp. 7343 - 7349 (2007)
Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Research 74.
Journal Article
171 (2), pp. 589 - 598 (2007)
Re-expression of a developmentally restricted potassium channel in autoimmune demyelination - Kv1.4 is implicated in oligodendroglial proliferation. American Journal of Pathology 75.
Journal Article
5, 41 (2006)
Overexpression of EagI potassium channels in clinical tumours. Molecular Cancer 76.
Journal Article
5, 42 (2006)
Ether à go-go potassium channel expression in soft tissue sarcoma patients. Molecular Cancer 77.
Journal Article
580 (21), pp. 5059 - 5066 (2006)
Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. FEBS Letters 78.
Journal Article
580 (12), pp. 2850 - 2852 (2006)
Potassium channels as tumour markers. FEBS Letters 79.
Journal Article
281 (19), pp. 13030 - 13037 (2006)
Silencing the activity and proliferative properties of the human EagI potassium channel by RNA interference. Journal of Biological Chemistry 80.
Journal Article
280 (33), pp. 29506 - 29512 (2005)
Glycosylation of Eag1 (Kv10.1) potassium channels - Intracellular trafficking and functional consequences. Journal of Biological Chemistry